After the establishment of the murine venous thrombosis model, Kessinger et al. [57] proved that the venous thrombosis burden can be reduced after a daily treatment with atorvastatin or rosuvastatin due to the interaction between multiple cell types and biomarkers (neutrophils, macrophages, IL-6, PAI-1, NETs, etc.). This evidence concerns the gene SERPINE1 and Venous thrombosis.